Antioxidative Capacity of Liver- and Adipose-Derived Mesenchymal Stem Cell-Conditioned Media and Their Applicability in Treatment of Type 2 Diabetic Rats.
Adipose Tissue
/ cytology
Animals
Antioxidants
/ pharmacology
Biomarkers
/ metabolism
Culture Media, Conditioned
/ pharmacology
Diabetes Mellitus, Experimental
/ complications
Diabetes Mellitus, Type 2
/ complications
Inflammation
/ complications
Intercellular Signaling Peptides and Proteins
/ metabolism
Kidney
/ drug effects
Lipids
/ blood
Liver
/ cytology
Male
Mesenchymal Stem Cells
/ drug effects
Myocardium
/ enzymology
Oxidative Stress
/ drug effects
Pancreas
/ pathology
Rats, Sprague-Dawley
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
09
2020
revised:
08
01
2021
accepted:
21
01
2021
entrez:
24
2
2021
pubmed:
25
2
2021
medline:
10
9
2021
Statut:
epublish
Résumé
Type 2 diabetes mellitus (T2DM) is mainly characterized by insulin resistance and impaired insulin secretion, which cannot be reversed with existing therapeutic strategies. Using mesenchymal stem cells (MSCs), cell-based therapy has been demonstrated in displaying therapeutic effects in T2DM for their self-renewable, differentiation potential, and immunosuppressive properties and higher levels of angiogenic factors. Stem cell therapies are complicated and have a serious adverse effect including tumor formation and immunogenicity, while using mesenchymal stem cell-conditioned media (MSC-CM) significantly reduces stem cell risk, maintaining efficacy and showing significantly higher levels of growth factors, cytokines, and angiogenic factors that stimulate angiogenesis and promote fracture healing in diabetes. In the present study, we investigated the therapeutic potential of the liver and adipose MSC-CM in diabetic endothelial dysfunction compared with standard insulin therapy. Fifty adult male Sprague Dawley rats were divided equally into 5 groups as follows: control, diabetic, diabetic+insulin, diabetic+liver MSC-CM, and diabetic+adipose MSC-CM; all treatments continued for 4 weeks. Finally, we observed that liver MSC-CM therapy had the most apparent improvement in levels of blood glucose; HbA1c; AGEs; lipid panel (cholesterol, TG, LDL, HDL, and total lipids); renal function (urea, uric acid, creatinine, and total protein); liver function (AST, ALT, ALP, bilirubin, and albumin); CPK; C-peptide; HO-1; inflammatory markers including IL-6, TNF-
Identifiants
pubmed: 33623636
doi: 10.1155/2021/8833467
pmc: PMC7875634
doi:
Substances chimiques
Antioxidants
0
Biomarkers
0
Culture Media, Conditioned
0
Intercellular Signaling Peptides and Proteins
0
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8833467Informations de copyright
Copyright © 2021 Mohamed M. Elshemy et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Hellenic J Cardiol. 2017 Sep - Oct;58(5):342-347
pubmed: 28089648
Cell Transplant. 2007;16(7):717-28
pubmed: 18019361
Stem Cells Int. 2019 Nov 3;2019:8628027
pubmed: 31781248
Cell Mol Biol (Noisy-le-grand). 2018 Mar 31;64(4):92-97
pubmed: 29631689
Immunol Lett. 2016 Apr;172:94-105
pubmed: 26930038
Immunol Rev. 2012 Sep;249(1):239-52
pubmed: 22889226
Biomed Res Int. 2014;2014:965849
pubmed: 25530971
Nutr Metab Cardiovasc Dis. 2018 Jun;28(6):592-599
pubmed: 29615288
Inflammopharmacology. 2020 Apr;28(2):585-601
pubmed: 31741175
Birth Defects Res C Embryo Today. 2009 Sep;87(3):232-48
pubmed: 19750517
J Tissue Eng Regen Med. 2012 Jul;6(7):559-69
pubmed: 21916015
Cytotechnology. 2014 Mar;66(2):299-307
pubmed: 23657630
Stem Cells Int. 2020 Feb 3;2020:6574010
pubmed: 32089708
Endocr J. 2015;62(4):339-52
pubmed: 25739585
J Cell Biochem. 2017 Aug;118(8):2037-2043
pubmed: 27791278
JAMA. 2017 Jun 27;317(24):2515-2523
pubmed: 28655017
Mol Ther. 2018 Aug 1;26(8):1921-1930
pubmed: 30005867
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Stem Cell Res Ther. 2018 Apr 19;9(1):110
pubmed: 29673394
Med Sci Monit. 2019 Apr 26;25:3069-3076
pubmed: 31023998
Mol Med Rep. 2018 Jun;17(6):8466-8474
pubmed: 29693163
J Pharmacol Pharmacother. 2016 Oct-Dec;7(4):159-164
pubmed: 28163536
Physiol Res. 2001;50(6):537-46
pubmed: 11829314
Am Fam Physician. 2005 Jun 1;71(11):2123-8
pubmed: 15952441
Stem Cells. 2016 Mar;34(3):627-39
pubmed: 26523620
Malays J Pathol. 2013 Jun;35(1):17-32
pubmed: 23817392
Stem Cells. 2006 Dec;24(12):2840-50
pubmed: 16945998
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Antioxid Redox Signal. 2018 Jul 10;29(2):111-127
pubmed: 29065700
Am J Physiol Gastrointest Liver Physiol. 2008 Nov;295(5):G1111-21
pubmed: 18832452
J Transl Med. 2011 Mar 22;9:29
pubmed: 21418664
Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):546-51
pubmed: 27366724
Front Biosci (Landmark Ed). 2009 Jan 01;14:4281-98
pubmed: 19273350
Am J Physiol Gastrointest Liver Physiol. 2006 Dec;291(6):G1089-99
pubmed: 16891300
Saudi J Biol Sci. 2019 Jan;26(1):118-128
pubmed: 30622415
Cytotherapy. 2015 Jul;17(7):940-7
pubmed: 25869301
Toxicol Rep. 2018 Aug 03;5:919-926
pubmed: 30225197
Toxicol Mech Methods. 2018 Oct;28(8):573-586
pubmed: 29781752
Stem Cell Res Ther. 2016 May 12;7(1):71
pubmed: 27176654
Eur J Clin Nutr. 2017 Jul;71(7):904-912
pubmed: 28402325
JAMA. 2002 Jan 16;287(3):360-72
pubmed: 11790216
Biomed Res Int. 2019 Feb 27;2019:3596287
pubmed: 30937310
Gastroenterology. 1997 Mar;112(3):960-7
pubmed: 9041259
J Cell Biochem. 2008 May 1;104(1):224-36
pubmed: 17979180
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8078-83
pubmed: 12048252
Cells Tissues Organs. 2018;206(6):317-329
pubmed: 31340210
Science. 2008 Dec 5;322(5907):1490-4
pubmed: 19056973